The Eyes Still Have It For Novartis Despite Sell-Off Rumors
Some Ophthalmology Assets Reported To Be Up For Grabs
Executive Summary
Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.
You may also be interested in...
Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb
The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.